<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506610</url>
  </required_header>
  <id_info>
    <org_study_id>K862-06-2001</org_study_id>
    <nct_id>NCT00506610</nct_id>
  </id_info>
  <brief_title>A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Flexible Escalating -Dose, Pilot Analgesic Efficacy Study of T-62 in Subjects With Postherpetic Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether T-62 is effective in providing relief of
      pain that can occur after an individual experiences a shingles outbreak, which is an
      infection in adults caused by the same virus that causes chicken pox.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity Difference (PID) scores (derived from data obtained using the 11 point Likert pain rating scale)</measure>
    <time_frame>During each Treatment Phase Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Various pain related assessment</measure>
    <time_frame>During each Treatment Phase Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression of Change (CGIC) and Subject Global Impression of Change (SGIC ) scores</measure>
    <time_frame>At each Treatment Phase Visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, intensity, relationship, and seriousness of treatment-emergent AEs by dose and by treatment group.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent changes in safety assessments</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of T-62 plasma concentrations</measure>
    <time_frame>At various timepoints during the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Postherpetic Neuralgia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-62</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a clinical diagnosis of Postherpetic Neuralgia (PHN)

          -  Experiencing pain for at least 3 months after the healing of shingles rash

          -  Has at least a weekly average pain intensity of equal to or greater than 4 out of 10

          -  Females must not be pregnant or breastfeeding and practicing an acceptable method of
             birth control, or be surgically sterile or post-menopausal

          -  Will not consume grapefruit or grapefruit juice during the study

        Exclusion Criteria:

          -  Has a current acute or unstable chronic disease other than Postherpetic Neuralgia
             (PHN)

          -  Has clinically important medical disorder

          -  Uses certain types of medications for heart conditions

          -  Unwilling/unable to discontinue use of medications for treatment of neuropathic pain

          -  Has a history of hypersensitivity to any medication or soy product

          -  Has liver or kidney disease

          -  Has asthma that required treatment within the last year

          -  Has HIV or hepatitis (other than hepatitis A)

          -  Has a history of alcohol abuse within the past 2 years

          -  Has a history of (within last 2 years) or currently abuses prescription or illegal
             drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bradenton Research Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anchor Research Center</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Research</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plains Medical Clinic</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent Moon Research</name>
      <address>
        <city>Murrells Inlet</city>
        <state>South Carolina</state>
        <zip>29576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odyssey Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2007</study_first_submitted>
  <study_first_submitted_qc>July 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <keyword>Pain</keyword>
  <keyword>Postherpetic Neuralgia</keyword>
  <keyword>Neuralgia, Postherpetic</keyword>
  <keyword>Shingles</keyword>
  <keyword>Herpes Zoster</keyword>
  <keyword>Neuropathic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

